Concerning clinical systemic treatment guidelines of ovarian cancer, these results underline the effectiveness of anti-angiogenic therapies such as VEGF-antibody therapies in patients with advanced tumor stages and remaining tumor [30]. The gene discussed is VEGFA; the disease is neoplasm.